Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pyrazole alcohol compound, its pharmaceutical composition and its application in medicine

A compound and pharmaceutical technology, applied in the field of medicinal chemistry, can solve problems such as fast metabolism, side effects of patients, and easy oxidation

Active Publication Date: 2022-03-04
GUIZHOU MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ligustrazine has poor fat solubility and low bioavailability, which leads to its fast metabolism, short half-life, and poor drug metabolism stability. In order to maintain an effective drug treatment concentration, it must be administered frequently clinically, which is easy to cause accumulation and poisoning, making its application restricted. certain limit
Edaravone is an antioxidant and free radical scavenger, which belongs to a small lipophilic molecule, which can form a high blood-brain barrier passage rate in the human body, and can prevent or treat neurons by protecting neurons in patients. The effect of treating cerebral apoplexy, but Edaravone has poor water solubility and is easy to oxidize in aqueous solution. In order to increase its water solubility and stability, it is often necessary to add alkaline substances and antioxidant substances in the preparation. The addition of these substances may give Patient causing unwanted side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrazole alcohol compound, its pharmaceutical composition and its application in medicine
  • Pyrazole alcohol compound, its pharmaceutical composition and its application in medicine
  • Pyrazole alcohol compound, its pharmaceutical composition and its application in medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0157] Example 1. 3-Methyl-1-(3,5,6-trimethylpyrazin-2-yl)-1H-pyrrol-5-ol (Compound 1): Yield 70.6%, oily liquid. 1 HNMR (500MHz, CDCl 3 )δ: 1 H NMR (400MHz, DMSO-d 6 ):δ:2.30(s,3H),2.51-2.54(m,9H),5.90(s,1H),12.2(s,1H,OH); HRMS(ESI) calculated value C 11 h 15 N 4 O[M+H] + :219.1246, measured value: 219.1247.

Embodiment 2

[0158] Example 2. 3-Ethyl-1-(3,5,6-trimethylpyrazin-2-yl)-1H-pyrrol-5-ol (compound 2): yield 65.6%, oily liquid. 1 HNMR (400MHz, d 6 -DMSO)δ: 1.14 (t, 3H, J=7.6Hz), 2.29 (s, 3H), 2.44-2.50 (m, 8H), 5.29 (s, 1H), 11.16 (s, 1H); HRMS (ESI ) Calculated value C 12 h 17 N 4 O[M+H] + :233.1402, measured value: 233.1396.

Embodiment 3

[0159] Example 3. 3-tert-amyl-1-(3,5,6-trimethylpyrazin-2-yl)-1H-pyrrol-5-ol (compound 3): 49.8% yield, white solid, m.p.167-168°C. 1 HNMR (400MHz, d 6 -DMSO) δ: 0.70(t, J=7.2Hz, 3H), 1.15(s, 6H), 1.49-1.54(m, 2H), 2.20(s, 3H), 2.44(s, 3H), 2.49(s ,3H),5.34(s,1H),11.07(s,1H); 13 CNMR (100MHz, d 6 -DMSO)δ: 9.1, 19.2, 20.8, 21.2, 27.1, 35.3, 35.5, 83.3, 142.7, 146.7, 148.4, 151.5, 153.5, 159.7; HRMS (ESI) calculated value C 15 h 23 N 4 o 2 [M+H] + : 275.1794, measured value 275.1789.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a 1-(3,5,6-trimethylpyrazine-2-yl)-5-pyrazolol compound, its tautomer, its pharmaceutical composition and its medicinal composition Applications. Wherein said 1-(3,5,6-trimethylpyrazine-2-yl)-5-pyrazolol compound has anti-platelet aggregation effect and dual action mechanism of nerve cell protection, including formula (I) Shown compound, its tautomer (Ia), or its stereoisomer, geometric isomer, hydrate, solvate, or pharmaceutically acceptable salt or prodrug: 1-(3 provided by the invention , 5,6-trimethylpyrazine-2-yl)-5-pyrazolol compounds and pharmaceutical compositions thereof can be used for the preparation of prevention and / or treatment and / or adjuvant treatment of cerebral palsy caused by thrombus and free radical excess Use in medicines for stroke, cardiovascular and cerebrovascular diseases, Alzheimer's disease and its complications.

Description

[0001] field of invention [0002] The invention belongs to the technical field of medicinal chemistry, and specifically relates to 1-(3,5,6-trimethylpyrazin-2-yl)-5-pyrazolol compounds, tautomers thereof, and pharmaceutical compositions thereof and applications in medicine. [0003] Background of the invention [0004] Stroke is a refractory disease that seriously endangers the safety of human life and is characterized by high morbidity, disability and mortality. The survey results of the World Health Organization show that the incidence of stroke in China ranks first in the world, twice as high as that in the United States, and the incidence of cerebrovascular diseases in my country has increased significantly in recent years, with an annual growth rate of 9%. It is estimated that by 2030 In my country, 4 million people will die of stroke every year. Therefore, stroke has become an important disease affecting the health of Chinese people, and it is urgent to carry out the pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D403/04C07D401/14C07D405/14C07D409/14A61K31/497A61P9/00A61P25/00A61P7/02A61P9/10
CPCA61P7/02A61P9/00A61P9/10A61P25/00C07D401/14C07D403/04C07D405/14C07D409/14
Inventor 樊玲玲汤磊李毅李永刘健出良钊
Owner GUIZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com